Article
A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies.
Molecular medicine (Cambridge, Mass.) - 1 Jul 1999
Soares I S, Barnwell J W, Ferreira M U, Gomes Da Cunha M, Laurino J P, Castilho B A, Rodrigues M M
Abstract excerpt
BACKGROUND: The 19 kDa C-terminal region of the merozoite surface protein 1 (MSP1(19)) has been suggested as candidate for part of a subunit vaccine against malaria. A major concern in vaccine development is the polymorphism observed in different plasmodial strains. The present study examined the extension and immunological relevance of the allelic polymorphism of the MSP1(19) from Plasmodium vivax, a major human...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.